Compare Viatris Inc (VTRS) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Block Inc — how do they compare? Viatris Inc trades at $16.45 (market cap $18.95B), while Block Inc trades at $79.02 (market cap $47.70B). The key difference: Block Inc is far larger — about 2.5× Viatris Inc's market cap, and Viatris Inc pays a 2.91% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| VTRS | XYZ | |
|---|---|---|
Market Cap | $18.95B | $47.70B |
Sector | Health | Technology |
52-Week High | $17.86 | $84.85 |
52-Week Low | $9.49 | $49.04 |
Enterprise Value | $31.07B | $42.61B |
Dividend Yield | 2.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
XYZ stock trades at $80.10, down 3.21% with a bearish technical signal. The company shows mixed fundamentals with strong revenue growth to $24.19B in 2025 but declining net income margins to 1.43%. Recent developments include expanding Cash App credit score access and applying for a national trust bank charter. Analyst consensus remains strongly bullish with 76% buy ratings and a $100.20 price target.
XYZ faces execution risks amid high P/E valuation of 143, though strategic initiatives in financial services provide growth catalysts. The stock offers 25% upside to consensus target but requires monitoring of profitability trends and regulatory approval for banking expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
